z-logo
Premium
In vivo evaluation of the lysine‐specific demethylase (KDM1A/LSD1) inhibitor SP‐2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC)
Author(s) -
Kurmasheva Raushan T.,
Erickson Stephen W.,
Han Ruolan,
Teicher Beverly A.,
Smith Malcolm A.,
Roth Michael,
Gorlick Richard,
Houghton Peter J.
Publication year - 2021
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.29304
Subject(s) - medicine , rhabdomyosarcoma , sarcoma , soft tissue sarcoma , osteosarcoma , oncology , cancer research , pathology
SP‐2577(Seclidemstat), an inhibitor of lysine‐specific demthylase KDM1A (LSD1) that is overexpressed in pediatric sarcomas, was evaluated against pediatric sarcoma xenografts. SP‐2577 (100 mg/kg/day × 28 days) statistically significantly ( p  < .05) inhibited growth of three of eight Ewing sarcoma (EwS), four of five rhabdomyosarcoma (RMS), and four of six osteosarcoma (OS) xenografts. The increase in EFS T/C was modest (<1.5) for all models except RMS Rh10 (EFS T/C = 2.8). There were no tumor regressions or consistent changes in dimethyl histone H3(K4), HOXM1, DAX1, c‐MYC and N‐MYC, or tumor histology/differentiation. SP‐2577 has limited activity against these pediatric sarcoma models at the dose and schedule evaluated.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here